NCT03235570View on ClinicalTrials.gov

A Safety and Tolerability Study of Pemigatinib in Japanese Subjects With Advanced Malignancies - (FIGHT-102)

PHASE1CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

August 1, 2017

Primary Completion Date

March 4, 2020

Study Completion Date

March 4, 2020

Conditions
Solid Tumors
Interventions
DRUG

Pemigatinib

Pemigatinib at the protocol-defined dose administered once daily.

Trial Locations (12)

464-8681

Aichi Cancer Center Hospital, Aichi

260-8717

Chiba Cancer Center, Chiba

277-8577

National Cancer Central Hospital East, Chiba

811-1395

Kyusyu Cancer Center, Fukuoka

920-8641

Kanazawa University Hospital, Ishikawa

241-8515

Kanagawa Cancer Center, Kanagawa

541-8567

Osaka International Cancer Institute, Osaka

362-0806

Saitama Cancer Center, Saitama

003-0804

Hokkaido Cancer Center, Sapporo

411-8777

Shizuoka Cancer Center, Shizuoka

104-0045

National Cancer Central Hospital, Tokyo

135-8550

JFCR Ariake Hospital, Tokyo

Sponsors

Lead Sponsor

Incyte Corporation
All Listed Sponsors
lead

Incyte Corporation

INDUSTRY

NCT03235570 - A Safety and Tolerability Study of Pemigatinib in Japanese Subjects With Advanced Malignancies - (FIGHT-102) | Biotech Hunter | Biotech Hunter